- Home
- ITRM vs PRME Comparison
ITRM vs PRME Comparison
Compare ITRM & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- PRME
- Stock Information
- Founded
- ITRM 2015
- PRME 2019
- Country
- ITRM Ireland
- PRME United States
- Employees
- ITRM N/A
- PRME N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- PRME Medicinal Chemicals and Botanical Products
- Sector
- ITRM Health Care
- PRME Health Care
- Exchange
- ITRM Nasdaq
- PRME Nasdaq
- Market Cap
- ITRM 37.7M
- PRME N/A
- IPO Year
- ITRM 2018
- PRME 2022
- Fundamental
- Price
- ITRM $1.08
- PRME $1.24
- Analyst Decision
- ITRM Strong Buy
- PRME Strong Buy
- Analyst Count
- ITRM 1
- PRME 8
- Target Price
- ITRM $5.00
- PRME $13.25
- AVG Volume (30 Days)
- ITRM 300.3K
- PRME 1.5M
- Earning Date
- ITRM 05-12-2025
- PRME 05-09-2025
- Dividend Yield
- ITRM N/A
- PRME N/A
- EPS Growth
- ITRM N/A
- PRME N/A
- EPS
- ITRM N/A
- PRME N/A
- Revenue
- ITRM N/A
- PRME $2,983,000.00
- Revenue This Year
- ITRM N/A
- PRME $56.92
- Revenue Next Year
- ITRM $150.10
- PRME $150.59
- P/E Ratio
- ITRM N/A
- PRME N/A
- Revenue Growth
- ITRM N/A
- PRME N/A
- 52 Week Low
- ITRM $0.81
- PRME $1.12
- 52 Week High
- ITRM $3.02
- PRME $8.27
- Technical
- Relative Strength Index (RSI)
- ITRM 32.84
- PRME 31.62
- Support Level
- ITRM $1.05
- PRME $1.20
- Resistance Level
- ITRM $1.16
- PRME $1.42
- Average True Range (ATR)
- ITRM 0.08
- PRME 0.17
- MACD
- ITRM -0.00
- PRME -0.00
- Stochastic Oscillator
- ITRM 13.04
- PRME 12.56
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.